Pace® Life Sciences announced the successful completion of an FDA inspection of its Small Molecule Center of Excellence in Research Triangle Park, North Carolina.
This milestone marks another successful FDA inspection across the analytical operations at Pace® Life Sciences, reinforcing the organization's long-standing commitment to quality, regulatory compliance, and data integrity.
"Achieving consistent positive FDA inspection outcomes across our analytical network reflects the strength of our quality systems, the expertise of our staff, and our unwavering commitment to scientific excellence," said Lou Forcellini, Head of Quality Assurance at Pace® Life Sciences. "Each successful inspection strengthens our clients' confidence in our capabilities and reinforces our mission to deliver reliable, high-quality results that ultimately help improve patient lives."
The Research Triangle Park facility provides comprehensive analytical support throughout the drug development and manufacturing lifecycle, including:
- Storage and stability testing
- Extractables and leachables (E&L) testing across container closure systems and manufacturing materials
- Analytical method development and validation
- Organic spectroscopy for the characterization, quantitation, and identification of small and large molecules
Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.